ClinicalTrials.gov
public full text
Public Domain
Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications Better Than Recombinant Human ACE2
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The hyaluronan receptor CD44 drives COVID-19 severity through its regulation of neutrophil migration#485266
- Helicobacter pylori regulates pro- and anti-inflammatory macrophage responses to promote bacterial survival#387650
- <i>Acinetobacter baumannii</i> lipooligosaccharide core region promotes CD14-dependent TLR4 endocytosis and enhances pathogenicity through interferon-β production#368468
- C3 activation products correlate with antibodies to lipid A in pauciarticular juvenile arthritis#488822
- The AAA+ superfamily of functionally diverse proteins#1133790
Record · ID 143642
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive